case_images: PMC6856955_01
case_images: Hematoxylin and eosin image showing that the pancreatic body (A: magnification, x20; D: magnification, x200), liver (B: magnification, x20; E: magnification, x200), and diaphragmatic (C: magnification, x20; F: magnification, x200) masses had a papillary architecture with folded nuclei with grooves, which is a characteristic of thyroid papillary carcinoma.
case_images: fendo-10-00759-g0001.jpg
case_images: PMC6856955_01_fendo-10-00759-g0001.jpg
case_images: F1
case_images: Pathological examination of the masses' tissues revealed carcinoma cells aggregating in papillary architecture, with folded nuclei, cells were forming nuclear grooves (Figure 1).
case_images: Whole-body 18-fluorodeoxyglucose positron-emission tomography/computed tomography image showing that some regions in the patient's body had widespread abnormal uptake.
case_images: fendo-10-00759-g0002.jpg
case_images: PMC6856955_01_fendo-10-00759-g0002.jpg
case_images: F2
case_images: The first revealed abnormal uptakes in the following locations: isthmus and left lobe of the thyroid, bilaterally in the parotid gland, left salivary gland, left cervical region, bilaterally in the lungs, pancreatic head, right kidney, and multiple cones, ribs, muscles and subcutaneous tissues (Figure 2).
case_images: Computed tomography (CT) images showing that the size of the metastatic lesions had decreased. (A,C,E,G). CT images of the metastatic lesions (white arrows) in the right pulmonary, right kidney, pancreatic head, and left gluteus maximus, respectively, before chemotherapy (lenvatinib). (B,D,F,H). CT images of the metastatic lesions (red arrows) after chemotherapy (lenvatinib).
case_images: fendo-10-00759-g0003.jpg
case_images: PMC6856955_01_fendo-10-00759-g0003.jpg
case_images: F3
case_images: After ~8 months of treatment, numerous metastatic lesions had lessened on computed tomography (Figure 3).